Header

DONGWHA PHARM-Anti-allergic asthma drug(Pd No. : 3078679)

(Updated : Feb/03/2017)
product information
Model Nm KDDF-201512-03
HS CODE 300390
M.O.Q
Ceritification
Keywords drug, asthma, dongwha, bio, medical
Seller ID itrade2000
  • SHARE




Pre-clinical study & clinical IND approval for the development of antiallergic asthma drug

[Development and Market Objectives]


  DW2008 is a natural product that inhibits both allergic inflammation and bronchoconstriction, and is currently under nonclinical GLP study for developing anti-allergic asthma drug. We plan to test on the toxicity and additional efficacy of DW2008 for global licensingout, as well as for local launching.



[Unmet Medical Need & Target Patients]


 Target population

•  Asthmatic patients who are ranked at step2(Mild) ~ step5(Severe) of GINA guideline.

•  Asthmatic patients, especially old age patients and pediatric patients, who show poor medication compliance in inhalation therapy.

•  Asthmatic patients who are not improved with leukotriene receptor antagonists. •  Asthmatic patients who show steroid resistance.


  Unmet Needs

•  Inhalation Corticosteroids(ICS) are current 1’st line therapeutic drugs of asthma, which exert good anti-inflammatory activities. But, ICS also show lots of regional adverse effects, steroid phobia, poor medication compliance.

•  Bronchodilators temporarily relieve asthmatic symptoms as relievers. But, they rather have risk for an asthma exacerbation in case of long term treatment, because they have not anti-inflammatory activities. They are also inhalers that cause poor medication compliance.

•  Leukotrine receptor antagonists(LTRA) are oral asthmatic drugs with over 90% market share, and have good medication compliance. But, they are usually used as add-on therapy to ICS, due to their insufficient efficacy.

•  Whereas there are inhaler combination drugs “ICS+LARB”, there are no oral drugs with anti-allergic inflammatory effects and bronchodilation effects.



[Status]


•  The candidate DW2008 is currently under GLP preclinical study according to OECD, ICH guideline in Korea •  The candidate DW2008 is currently under drug positioning study in 5 asthma subtype animal models and searching specific biomarkers for setting up optimal patient selection criteria. 



[Intellectual Property]


•  Patent pending: Korea (2) PCT(1)

•  Covering worldwide



[Competitive Advantages]


•Efficacy & MoA

-  Dual effects (anti-allergic inflammatory effect and bronchodilation effect)

-  Superior effects of DW2008 versus Montelukast(allergy inflammation) or Ambroxol(Mucosal Secretion)

-  Th2/Th17 selectivity

-  Identification of multiple targets relating to anti-allergic inflammation and bronchodilation


•CMC

-  Well-controlled CMC

-  Using GAP(Good agriculture practice) certificated botanical material

-  Identification of over 80% components (in HPLC peak area)


•Compliance and Others

-  Better medical compliance than inhalation

-  Beyond indications to other allergic diseases or respiratory diseases, such as rhinitis, atopic dermatitis, and COPD.


Company Information

company information
Contact Person Sun Tae Hwang
Company DONGWHA PHARM CO.,LTD.
Address
Homepage www.dong-wha.co.kr , http://seller.buykorea.org/dongwha-pharm--1036300
Tel 0220219300 Fax 027784373
Biz. Type Est. Year
Employees Annual Export USD 0~1 mn
Related Business Event List
InCheon BIOplus GP Business Meeting 2017-09-13 ~ 2017-09-13
Global Bio Pharma Plaza(GBPP 2017) 2017-11-27 ~ 2017-11-28
Innovation & Technology Business Partnering 2017 COEX Intercontinental, Seoul, South Korea 2017-03-29 ~ 2017-03-30
CPhI World Wide 2016 2017-10-24 ~ 2017-10-26
InnoMedi 2017-03-29 ~ 2017-03-29
Go to the top of the page
Loading...